- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different:" Meet the Nonprofit Taking on Generic Drug Shortages
In January of last year, several hospital groups, representing approximately 450 US hospitals, revealed plans to form a nonprofit generic drug company in a bold move designed to address generic drug shortages and high prices affecting their hospitals.
In January of last year, several hospital groups, representing approximately 450 US hospitals, revealed plans to form a nonprofit generic drug company in a bold move designed to address generic drug shortages and high prices affecting their hospitals.
The nonprofit drug maker that resulted from that effort is Civica Rx, which this January announced that it had added another 12 health systems to its ranks, bringing the total of hospitals involved in the venture to 750. Several major philanthropic organizations have also joined up. This year, Civica hopes to bring the first of its generics to hospitals and healthcare systems.
This week on the podcast, we're speaking with Civica’s Heather Wall. She’s the organization’s chief commercial officer, and was recently named one of Modern Heatlhcare’s women leaders to watch.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
